These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 6402000

  • 1. Effects of dazoxiben on exercise performance in chronic stable angina.
    Reuben SR, Kuan P, Cairns J, Gyde OH.
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):83S-86S. PubMed ID: 6402000
    [Abstract] [Full Text] [Related]

  • 2. Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease.
    Hutton I, Tweddel AC, Rankin AC, Walker ID, Davidson JF.
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):79S-82S. PubMed ID: 6681709
    [Abstract] [Full Text] [Related]

  • 3. Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris.
    Hendra T, Collins P, Penny W, Sheridan DJ.
    Int J Cardiol; 1984 Mar; 5(3):382-5. PubMed ID: 6538553
    [Abstract] [Full Text] [Related]

  • 4. Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test.
    Mogensen F, Knudsen JB, Rasmussen V, Kjøller E, Gormsen J.
    Thromb Res; 1985 Jan 15; 37(2):259-66. PubMed ID: 4038824
    [Abstract] [Full Text] [Related]

  • 5. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
    Shikano M, Ogawa K, Ito T, Chen LS, Ito Y, Imaizumi M, Uno T, Tsutsumi S, Satake T.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Jan 15; 13():375-7. PubMed ID: 3159226
    [No Abstract] [Full Text] [Related]

  • 6. Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
    Dodd NJ, Gordge MP, Weston MJ.
    Br J Clin Pharmacol; 1983 Jan 15; 15 Suppl 1(Suppl 1):67S-70S. PubMed ID: 6337605
    [Abstract] [Full Text] [Related]

  • 7. Dazoxiben in stable angina.
    Hendra T, Collins P, Penny W, Sheridan D.
    Lancet; 1983 May 07; 1(8332):1041. PubMed ID: 6133076
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor.
    Burke SE, Lefer AM, Smith GM, Smith JB.
    Br J Clin Pharmacol; 1983 May 07; 15 Suppl 1(Suppl 1):97S-101S. PubMed ID: 6681711
    [Abstract] [Full Text] [Related]

  • 9. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
    Schumacher WA, Lucchesi BR.
    J Pharmacol Exp Ther; 1983 Dec 07; 227(3):790-6. PubMed ID: 6418881
    [Abstract] [Full Text] [Related]

  • 10. Selective thromboxane synthetase inhibitor and ischemic heart disease.
    Ito T, Ogawa K, Watanabe J, Chen LS, Shikano M, Imaizumi M, Shibata T, Ito Y, Miyazaki Y, Satake T.
    Biomed Biochim Acta; 1984 Dec 07; 43(8-9):S125-32. PubMed ID: 6542777
    [No Abstract] [Full Text] [Related]

  • 11. Haemodynamic and metabolic effects of dazoxiben at rest and during atrial pacing.
    Kiff PS, Bergman G, Atkinson L, Jewitt DE, Westwick J, Kakkar VV.
    Br J Clin Pharmacol; 1983 Dec 07; 15 Suppl 1(Suppl 1):73S-77S. PubMed ID: 6681708
    [Abstract] [Full Text] [Related]

  • 12. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
    Dale J, Thaulow E, Myhre E, Parry J.
    Thromb Haemost; 1983 Oct 31; 50(3):703-6. PubMed ID: 6689091
    [Abstract] [Full Text] [Related]

  • 13. Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease.
    Thaulow E, Dale J, Myhre E.
    Am J Cardiol; 1984 May 01; 53(9):1255-8. PubMed ID: 6538740
    [Abstract] [Full Text] [Related]

  • 14. Dazoxiben.
    Lancet; 1983 Mar 19; 1(8325):627-8. PubMed ID: 6131306
    [No Abstract] [Full Text] [Related]

  • 15. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
    FitzGerald GA, Brash AR, Oates JA, Pedersen AK.
    J Clin Invest; 1983 Oct 19; 72(4):1336-43. PubMed ID: 6355181
    [Abstract] [Full Text] [Related]

  • 16. Dazoxiben examined for platelet inhibitory effect in an artificial circulation.
    Goldman M, Hall C, Hawker RJ, McCollum CN.
    Br J Clin Pharmacol; 1983 Oct 19; 15 Suppl 1(Suppl 1):61S-65S. PubMed ID: 6681706
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
    Zipser RD, Kronborg I, Rector W, Reynolds T, Daskalopoulos G.
    Gastroenterology; 1984 Dec 19; 87(6):1228-32. PubMed ID: 6593268
    [Abstract] [Full Text] [Related]

  • 18. Effect of the thromboxane synthetase inhibitor Dazoxiben (UK 37-248) on the metabolism of antipyrine in patients with enhanced platelet aggregation.
    Staiger C, Walter E, Wang NS, Schuhmacher E, de Vries J, Weber E.
    Int J Clin Pharmacol Ther Toxicol; 1984 May 19; 22(5):250-3. PubMed ID: 6540249
    [Abstract] [Full Text] [Related]

  • 19. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.
    Belch JJ, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, Leiberman P, Forbes CD, Prentice CR.
    Br J Clin Pharmacol; 1983 May 19; 15 Suppl 1(Suppl 1):113S-116S. PubMed ID: 6337601
    [Abstract] [Full Text] [Related]

  • 20. Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers.
    Parry MJ, Randall MJ, Tyler HM, Myhre E, Dale J, Thaulow E.
    Lancet; 1982 Jul 17; 2(8290):164. PubMed ID: 6123880
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.